Iranian
Biomedical Journal
Volume 28, Issue 7 (Special Issue 2024)
IBJ 2024, 28(7): 222-222 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Vaziri Nezamdoust F, Gahramanpoor M, Pazhang Y, Rahbarghazi R. Resveratrol Exerted Anti-Angiogenic Effects on Human Adenocarcinoma Cells. IBJ 2024; 28 (7) :222-222
URL: http://ibj.pasteur.ac.ir/article-1-4645-en.html
URL: http://ibj.pasteur.ac.ir/article-1-4645-en.html
Abstract:
Introduction: Colorectal cancers have been considered devastating pathological conditions with high prevalence rates in developing and developed countries. Finding effective oncostatic compounds with fewer side effects is central to the debate. Phytocompounds with varied biological effects have been used to prevent and treat different tumors. In the present study, we investigated the tumoricidal effects of resveratrol on human colorectal HT-29 cells.
Methods and Materials: Cells were treated with different concentrations of resveratrol (25, 50, and 100 µM) for 48 hours. The survival rate, expression, and protein levels of angiopoietin (Ang)-1 and -2 were monitored using MTT, real-time PCR, and Western blotting.
Result: Data indicated the reduction of survival rate in HT-29 cells in a dose-dependent manner after being exposed to 25, 50, and 100 µM of resveratrol compared to the control group (p = 0.05). Based on real-time PCR and Western blot analyses, increasing doses of resveratrol can reduce the expression and protein levels of Ang-1 and -2 in a dose-dependent manner (p = 0.05).
Conclusion and Discussion: Resveratrol can reduce the angiogenesis properties of human colorectal HT-29 cells by suppressing Ang-1 and -2 in vitro conditions.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |